Based on the provided data, the year-on-year variation in the use of respiratory system medicines in Australia is as follows:
- 2024: 27.4 Units
- 2025: 26.7 Units (-2.6% YoY)
- 2026: 26.2 Units (-1.9% YoY)
- 2027: 25.7 Units (-1.9% YoY)
- 2028: 25.4 Units (-1.2% YoY)
The Compound Annual Growth Rate (CAGR) over the five-year period from 2024 to 2028 is -1.9%.
Future trends to watch include advancements in respiratory treatments, increased management of respiratory conditions through preventive measures, and potential impacts from innovations in telemedicine and remote monitoring. Additionally, public health initiatives and changes in environmental policies could influence the overall consumption of respiratory system medicines.
